With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
Artivion (NYSE:AORT) this week announced it received FDA humanitarian device exemption (HDE) for its AMDS Hybrid Prosthesis.
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...
Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.
Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 ...
A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...
Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
BeiGene (BGNE) “announced the presentation of new clinical data at the 66th American Society of Hematology Annual Meeting and Exposition, ...
Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who were treated with revumenib, with no new safety signals found.